Post-ischaemic treatment with the prostacycline analogue TTC-909 reduces ischaemic brain injury.
The effects of stable PGI analogue TTC-909 on CBF and glucose metabolism was studied in the chronic stage of cerebral ischaemia produced by occluding the distal MCA in SHRSP. Administration of TTC-909 (100 ng/kg/day during 7 days) prevented the development of ischaemic oedema and improved secondary metabolic derangement coupled to flow in postischaemic tissues, particularly in the ischaemic rim.
Shima
K
K
Department of Neurosurgery, National Defense Medical College, Saitama, Japan.
Ohashi
K
K
Umezawa
H
H
Chigasaki
H
H
Karasawa
Y
Y
Okuyama
S
S
Araki
H
H
Otomo
S
S
D000818:Animals; D001921:Brain / Q000378:metabolism; D002545:Brain Ischemia / Q000378:metabolism / Q000503:physiopathology*; D002560:Cerebrovascular Circulation / Q000187:drug effects; D002561:Cerebrovascular Disorders / Q000209:etiology; D004198:Disease Susceptibility; D011464:Epoprostenol / Q000031:analogs & derivatives* / Q000494:pharmacology; D005947:Glucose / Q000378:metabolism; D008297:Male; D051381:Rats; D011918:Rats, Inbred SHR / Q000502:physiology; D014018:Tissue Distribution
C068518:TTC 909; D011464:Epoprostenol; D005947:Glucose